Teva Pharmaceuticals
TEVA
824 hedge funds and large institutions have $30B invested in Teva Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 77 funds opening new positions, 241 increasing their positions, 350 reducing their positions, and 69 closing their positions.
23% more funds holding in top 10
Funds holding in top 10: 47 → 58 (+11)
12% more first-time investments, than exits
New positions opened: 77 | Existing positions closed: 69
1.28% more ownership
Funds ownership: 54% → 55.28% (+1.3%)
4% more call options, than puts
Call options by funds: $563M | Put options by funds: $541M
1% more funds holding
Funds holding: 819 → 824 (+5)
2% less capital invested
Capital invested by funds: $30.6B → $30B (-$636M)
31% less repeat investments, than reductions
Existing positions increased: 241 | Existing positions reduced: 350
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Paulson & Co
New York
|
+$1.04B |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
+$575M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$509M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$357M |
| 5 |
HCM
Highfields Capital Management
Boston,
Massachusetts
|
+$248M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair & Company
Chicago,
Illinois
|
-$348M |
| 2 |
MIP
Mondrian Investment Partners
London,
United Kingdom
|
-$331M |
| 3 |
Lazard Asset Management
New York
|
-$309M |
| 4 |
PC
PointState Capital
New York
|
-$308M |
| 5 |
Boston Partners
Boston,
Massachusetts
|
-$243M |
TEVA Hedge Fund Activity: Q3 2015 in Review
824 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q3 2015, worth a combined $30B — down 2.1% from $30.6B a quarter earlier.
Buyers outnumbered sellers: 77 funds opened new TEVA positions and 69 closed out — a net gain of 8 holders — while 241 added to existing stakes and 350 trimmed.
The largest buyer was Paulson & Co, adding an estimated $1.04B. The largest seller was William Blair & Company, cutting an estimated $348M.
- 824 institutional investors held Teva Pharmaceuticals (TEVA) as of Q3 2015, up from 819 in Q2 2015.
- Funds reported $30B of Teva Pharmaceuticals stock for Q3 2015, down 2.1% quarter-over-quarter.
- 77 funds opened new Teva Pharmaceuticals positions in Q3 2015 and 69 closed out, a net change of +8 holders.
- The largest Teva Pharmaceuticals buyer in Q3 2015 was Paulson & Co, an estimated $1.04B added.
- The largest Teva Pharmaceuticals seller in Q3 2015 was William Blair & Company, an estimated $348M sold.
Based on aggregated 13F filings for Q3 2015.